Anabolic Steroid Addiction: Effects, Signs & Treatment

Anabolic steroid use is addictive: DSM-5-TR has no standalone anabolic-androgenic steroid diagnosis — problematic AAS use is coded under Other (or Unknown) Substance Use Disorder, specifying AAS, and AAS withdrawal is likewise not a named DSM syndrome, evaluated against the same 11 substance use disorder criteria applied to other addictive substances. Two to three criteria indicate a mild disorder, four to five a moderate disorder, and six or more a severe disorder.

Chronic AAS use suppresses the HPG axis, and the body stops producing its own testosterone once it relies on an external source. This suppression creates physiological reliance on continued dosing, because stopping AAS leaves testosterone levels below normal until the axis recovers. Crucially, AAS dependence is not the euphoric-intoxication addiction seen with opioids or stimulants — it is largely driven by fear of losing muscle mass and by muscle dysmorphia, a distinct psychological mechanism. This body-image distortion responds to dual diagnosis treatment that addresses the mood or body-image condition alongside the substance use disorder, and it frequently escalates through muscle dysmorphia, the body-image disorder examined next.

Muscle dysmorphia, popularly called bigorexia, is a subtype of body dysmorphic disorder in which a person perceives their body as insufficiently muscular, and it is the central psychological engine behind anabolic steroid initiation and escalation. The condition produces a documented paradox: users grow measurably bigger yet feel increasingly inadequate.

The National Institute on Drug Abuse classifies anabolic steroids among appearance and performance enhancing drugs (APEDs), a framing that captures why AAS dependence differs from a euphoria-driven high. Roughly 30% of anabolic-androgenic steroid users develop a dependence syndrome — continued use despite adverse physical, psychosocial, or occupational consequences (Kanayama, Brower, Wood, Hudson & Pope, 2009). Rapid appearance and strength gains reinforce that pattern through the brain's dopamine reward pathway, so each visible improvement rewards the next cycle even as harm accumulates. Because muscle dysmorphia sits within the obsessive-compulsive spectrum, it responds to the same evidence-based care used in obsessive-compulsive disorder treatment, and clinicians screen for it alongside the behavioral and physical signs of steroid addiction that appear next.

The signs of steroid addiction span behavioral signs such as cycling and stacking, physical signs such as gynecomastia and testicular atrophy, and psychological signs such as mood swings and aggression, and these signs intensify as dependence on continued dosing deepens. Recognizing signs across all three categories distinguishes steroid addiction from ordinary athletic training.

Behavioral signs include cycling and stacking patterns — alternating on- and off-drug periods and combining multiple compounds — doctor shopping or sourcing AAS on the black market, compulsive training and gym behavior, and continued use despite explicit medical warnings. Physical signs include rapid muscle gain disproportionate to training history, severe acne, gynecomastia, testicular atrophy, and elevated blood pressure. Psychological signs include mood swings, irritability and aggression — often called "roid rage," a documented effect that remains inconsistent across users rather than universal — and preoccupation with physique. These markers overlap with the broader framework covered in signs of drug addiction, though testicular atrophy and gynecomastia set AAS apart from other substances. The physical and psychological signs above point directly to the effects and risks that accumulate with continued steroid use.

Steroid use produces short-term effects such as acne, fluid retention, mood changes, sleep disturbance, and increased aggression, while long-term use causes the cardiovascular and hepatic damage that account for the most serious AAS-related morbidity. Short-term effects resolve once a cycle ends, but the organ damage from repeated cycling accumulates.

Cardiovascular damage includes cardiomyopathy, left ventricular hypertrophy, adverse shifts in blood lipids, and elevated risk of heart attack and stroke. Hepatic damage includes liver toxicity and peliosis hepatis, a condition marked by blood-filled cysts in the liver. These two organ systems account for the leading causes of AAS-related death and disability, distinct from the respiratory-depression overdose risk associated with opioids and sedatives. AAS carries no equivalent acute overdose mechanism; danger instead comes from cumulative cardiac and hepatic strain and from combining AAS with other substances. Endocrine disruption compounds the picture: men develop infertility and testicular atrophy, while women who use AAS experience virilization effects, including voice deepening and clitoral enlargement. Both men and women face infertility from HPG axis suppression that can persist after steroid use stops — a suppression pattern that produces the withdrawal symptoms described next.

Steroid withdrawal is not the classic physical syndrome associated with alcohol, benzodiazepines, or opioids, is not associated with the seizure risk seen in alcohol or benzodiazepine withdrawal, and instead follows abrupt discontinuation as a DSM-5-TR-recognized syndrome driven by suppressed endogenous testosterone from HPG axis disruption.

This withdrawal syndrome includes fatigue, depressed mood, decreased libido, insomnia, and cravings to resume AAS use. Symptoms can persist for weeks to months while the HPG axis recovers and the body resumes its own testosterone production. Depression severity and suicidality risk during this phase require clinical monitoring, because the same hormonal suppression that produces fatigue and low mood can deepen into a diagnosable depressive episode. The duration of that phase — and the post-cycle crash that defines it — is examined next.

Anabolic steroid withdrawal typically lasts several weeks to months, and its most dangerous feature is the post-cycle crash — a hypogonadal state in which suppressed endogenous testosterone drives major depression, loss of libido, and elevated suicidal ideation. Unlike alcohol or opioid withdrawal, the AAS crash is rarely physically life-threatening, yet the psychiatric risk is the phase that demands supervision.

Reported clinical features of AAS withdrawal include fatigue, myalgia, restlessness, insomnia, low mood and libido, anorexia, suicidal ideation, body-image dissatisfaction, and steroid cravings (Sharma et al., Best Pract Res Clin Endocrinol Metab, 2022). The depressive window is the clinically dangerous one: because the sharp drop in testosterone can persist for months while the HPG axis recovers, this is when a person is most at risk. Recovery often involves medically supervised hormone restoration — clinicians sometimes reference post-cycle therapy, though non-medical PCT protocols sourced online are no substitute for supervised endocrine and psychiatric care. When low mood deepens into a depressive episode during this window, integrated depression treatment becomes central, which is why steroid addiction care pairs medical monitoring with psychiatric support as the next section details.

Steroid addiction is treated with medical monitoring of cardiac and hepatic function, psychiatric care for the mood symptoms of HPG axis recovery, and behavioral therapy for the muscle dysmorphia that drives continued use, because no FDA-approved medication treats AAS use disorder specifically. Treatment begins with an ASAM Criteria assessment that matches the severity of use and any co-occurring condition to the appropriate level of care.

Medical monitoring tracks cardiac and hepatic function throughout treatment, since these two organ systems carry the highest AAS-related risk. Psychiatric and endocrinology-informed care addresses the mood symptoms that surface while the HPG axis recovers, and cognitive behavioral therapy targets the muscle dysmorphia and body-image distortion that frequently drive continued use. Ascend Recovery Center delivers this care across a partial hospitalization program, an intensive outpatient program, and step-down outpatient care. Clients transition into an outpatient treatment program as cardiac, hepatic, and mood symptoms stabilize. This structured continuum is how a person gets help for steroid addiction in Palm Beach Gardens.

Getting help for steroid addiction starts with a confidential clinical assessment and insurance verification, not with stopping the drug unsupervised, because abrupt cessation can worsen the depressive withdrawal symptoms described above. A structured evaluation identifies cardiac, hepatic, and psychiatric risk before any treatment plan begins.

Ascend Recovery Center is a Joint Commission-accredited, Florida DCF-licensed outpatient provider located in Palm Beach Gardens, serving clients across South Florida. The same clinical team that monitors cardiac and hepatic recovery during HPG axis restoration also treats the underlying mood and body-image drivers of continued steroid use, delivering one integrated plan instead of fragmented care. Contact Ascend Recovery Center at (561) 956-1082 to schedule a confidential assessment and begin treatment.